The acquired company provides pre-operative diagnostics and quantitative data software solution that improves treatment decisions for patients with chronic and acute spine issues.
Its ProfileESP, Vertebral Motion Analysis (VMA) technology and integrated Surgical Planning Solution is expected to further fortify Wenzel’s existing spine fusion-related product portfolio by adding key diagnostic and decision-making tools.
Wenzel SpineCEOChad Neely said: “Solutions in diagnostics and surgical planning tools play a critical role in the advancement of Wenzel Spine’s total solution offering in minimally invasive surgery.
“We are very excited to have the experience, expertise and dedication of the Statera Spine team as part of Wenzel Spine. The addition of these unique diagnostic and planning solutions complement our existing minimally invasive implant technology and allow us to bring comprehensive solutions to spine surgeons and their patients. By combining diagnostics with our MIS implant portfolio, we can continue to advance minimally invasive spine surgery, while reducing overall cost.”
The new Wenzel Spine Diagnostics service products will provide physicians with the ability to utilise full spine alignment data, angulation and translation and disc height data at each spine level.
Wenzel Spine is also gearing up to launch its Surgical Planning Solution in the US at the beginning of next year.
Meanwhile, in a separate development, US-based medical device companyExsoMed Corporation closed the second round of financing.
This investment round, which was joined by both existing investors and new individuals, is said to be at an increased valuation from its seed funding round.
Proceeds from the round will be used by ExsoMedto boost its core business, enhance its commitment to surgeon education, and enhance upcoming product launches slated towards the end of this year and at the beginning of next year.
ExsoMed chief operating and financial officer Daniel Mickelsen said: “We are gratified by the market’s enthusiasm for ExsoMed, not just from our individual investors, but also from our expanded distribution network and surgeon users.
“This influx of capital ensures that ExsoMed will support our rapid growth and continue to deliver innovation to the hand surgery market, all while creating value for our shareholders.”